Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The peptide
F2L
was previously characterized as a high-affinity natural agonist for the human formyl peptide receptor (FPR) 3.
F2L
is an acetylated 21-aa peptide corresponding with the N terminus of the intracellular
heme-binding protein
1 (HEBP1). In the current work, we have investigated which proteases were able to generate the
F2L
peptide from its precursor HEBP1. Structure-function analysis of
F2L
identified three amino acids, G(3), N(7), and S(8), as the most important for interaction of the peptide with FPR3. We expressed a C-terminally His-tagged form of human HEBP1 in yeast and purified it to homogeneity. The purified protein was used as substrate to identify proteases generating bioactive peptides for FPR3-expressing cells. A conditioned medium from human monocyte-derived macrophages was able to generate bioactivity from HEBP1, and this activity was inhibited by pepstatin A. Cathepsin D was characterized as the protease responsible for HEBP1 processing, and the bioactive product was identified as
F2L
. We have therefore determined how
F2L
, the specific agonist of FPR3, is generated from the intracellular protein HEBP1, although it is unknown in which compartment the processing by
cathepsin D
occurs in vivo.
...
PMID:Processing of HEBP1 by cathepsin D gives rise to F2L, the agonist of formyl peptide receptor 3. 2170 60